Q32 Bio soars as hair-loss drug shows scalp hair regrowth in mid-stage study

Q32 Bio

13/07/2026 12:13

** Shares of biotech firm Q32 Bio QTTB.O jumps 56% to $17.54 premarket
** Co says bempikibart helped patients with alopecia areata, an autoimmune disease that causes patchy or severe hair loss when the immune system attacks hair follicles
** Patients treated for 36 weeks saw a 35.3% average improvement in hair regrowth, measured by SALT score, which measures the percentage of scalp affected by hair loss
** About 40% of patients achieved significant scalp hair coverage, the company said
** Trial enrolled 33 patients, including some who had previously received JAK inhibitors, a common class of alopecia treatments
** Co plans a larger registration-focused study in 2027 and expects to present additional results at a future medical meeting
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))